Muscular Dystrophy Awareness Month: Raising awareness, raising hope
Every September, communities across the world come together for Muscular Dystrophy Awareness Month. It is a moment of visibility for patients, families, clinicians, and researchers who live with or study rare neuromuscular disorders (NMDs). These conditions, such as Duchenne Muscular Dystrophy and Centronuclear Myopathy, cause progressive muscle weakness, severely affecting mobility and independence.
For families, the impact is profound. Daily life is reshaped by physical limitations, complex care routines, and the emotional toll of uncertainty. For health systems, the challenge lies in delivering lifelong care in the absence of effective therapies.
Despite decades of effort, traditional drug development pipelines have produced few approved treatments. This is largely due to the unique challenges of rare diseases: small patient populations, high costs, and high failure rates. But innovation is on the horizon.
DREAMS: a European response to an unmet need
Funded by the European Union, the DREAMS project (Drug Repurposing with Artificial Intelligence for Muscular Disorders) is reimagining how therapies for rare neuromuscular diseases can be discovered, validated, and delivered.
The project brings together nine organisations from six countries, coordinated by the CECS/I-Stem Institute in France. Its mission is clear: use cutting-edge science to accelerate the path from discovery to patient impact.
By integrating artificial intelligence (AI), stem cell technology, and adaptive clinical trial design, DREAMS is laying the foundations for a new, reusable drug discovery platform for rare diseases.
From stem cells to AI: a powerful combination
One of DREAMS’ most innovative aspects is its use of induced pluripotent stem cells (iPSCs) — cells that can be reprogrammed into patient-specific skeletal muscle cells. These cells allow scientists to replicate the disease in the lab and study its molecular mechanisms more closely.
Coupled with this, AI-driven algorithms help identify potential drug targets and screen molecules at unprecedented speed. The benefits are clear:
- Faster discoveries: reducing the time to find viable drug candidates.
- Lower costs: making research more sustainable and efficient.
- Safer outcomes: minimising side effects and avoiding ineffective therapies.
- Wider reach: enabling drug repurposing and exploring new uses for existing medicines.
This dual approach creates a dynamic cycle: data from stem cell models informs AI predictions, while AI-driven insights guide further laboratory validation. Together, they form a closed-loop system of discovery with the potential to transform how we approach rare neuromuscular disorders.
Tackling five rare diseases and beyond
DREAMS focuses on five genetic neuromuscular disorders that, despite their differences, share common pathways such as autophagy dysfunction and desmin disorganisation:
- Duchenne Muscular Dystrophy (DMD)
- Centronuclear Myopathy (CNM)
- Emery-Dreifuss Muscular Dystrophy (EDMD2)
- Pompe Disease (Glycogen-Storage Disease II)
- Danon Disease
By targeting these shared mechanisms, DREAMS aims to create therapies with broader applications, treatments that can potentially serve multiple rare conditions at once.
Rethinking clinical trials for rare diseases
Even when potential therapies are found, testing them in rare disease populations is a major hurdle. Classical trial models require large numbers of patients, which simply do not exist for most rare disorders.
To address this, DREAMS is developing adaptive clinical trial designs. These models allow for smaller, more flexible patient groups while still meeting rigorous safety and efficacy standards. Importantly, patients and regulatory experts are actively involved in shaping these trials, ensuring that the process remains ethical, inclusive, and impactful.
This approach could set a new gold standard for rare disease trials across Europe, opening the door to faster approvals and broader access.
Beyond science: societal and economic impact
The ambition of DREAMS is not only scientific but deeply societal. Rare neuromuscular disorders represent hundreds of conditions that profoundly affect quality of life. By accelerating drug discovery, DREAMS can:
- Improve daily lives of patients and families.
- Reduce economic burdens on healthcare systems.
- Generate new knowledge for the scientific community.
- Create reusable tools for future research.
This reflects the wider vision of the European Union: to ensure research investments deliver not just innovation but tangible social impact.
Muscular Dystrophy Awareness Month: why now matters
Muscular Dystrophy Awareness Month is more than a campaign. It is a reminder that rare disease research must remain a political, scientific, and social priority. It highlights the resilience of patients, the dedication of caregivers, and the urgent need for solidarity.
For DREAMS, it is an opportunity to show how collaborative European science is responding to that call. By bringing together AI experts, stem cell researchers, clinicians, and patient voices, the project demonstrates the power of multidisciplinary, cross-border collaboration.
Looking ahead: turning dreams into therapies
While much work remains, DREAMS is charting a path toward a future where therapies for neuromuscular disorders are discovered faster, tested smarter, and delivered sooner.
As Muscular Dystrophy Awareness Month reminds us: awareness must lead to action. DREAMS is one step forward, from laboratories to lives, in the journey toward hope for patients and families across Europe.
